Exploring CD22 as an Alternative Target in B-cell Hematologic Malignancies: A Comprehensive Review of Study Design, Clinical Implications, and Future Perspectives
Abstract: Chimeric antigen receptor (CAR)-T cell therapy targeting CD19 has revolutionized the treatment landscape for patients with relapsed or refractory (R/R) B-cell malignancies. However, the emergence of relapse with CD19-negative…
